Next Article in Journal
Evaluation of the Nutritional and Health Values of Selected Polish Mushrooms Considering Fatty Acid Profiles and Lipid Indices
Next Article in Special Issue
Development of Novel Pyridine-Thiazole Hybrid Molecules as Potential Anticancer Agents
Previous Article in Journal
Design of Deep Eutectic Systems: Plastic Crystalline Materials as Constituents
Previous Article in Special Issue
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 19
10.3390/molecules27196206
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hybrids of 1,4-Quinone with Quinoline Derivatives: Synthesis, Biological Activity, and Molecular Docking with DT-Diaphorase (NQO1)

by
Monika Kadela-Tomanek
1,*,
Maria Jastrzębska
2,
Elwira Chrobak
1,
Ewa Bębenek
1 and
Małgorzata Latocha
3
1
Department of Organic Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, 4 Jagiellońska Str., 41-200 Sosnowiec, Poland
2
Silesian Center for Education and Interdisciplinary Research, University of Silesia, Institute of Physics, 1a Pułku Piechoty 75 Str., 41-500 Chorzów, Poland
3
Department of Cell Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, 8 Jedności Str., 41-200 Sosnowiec, Poland
*
Author to whom correspondence should be addressed.
Molecules 2022, 27(19), 6206; https://doi.org/10.3390/molecules27196206
Submission received: 9 August 2022 / Revised: 14 September 2022 / Accepted: 17 September 2022 / Published: 21 September 2022
(This article belongs to the Special Issue Novel Design and Synthesis of Anticancer Agents)
Browse Figures
Versions Notes

Abstract

:
Hybrids 1,4-quinone with quinoline were obtained by connecting two active structures through an oxygen atom. This strategy allows to obtain new compounds with a high biological activity and suitable bioavailability. Newly synthesized compounds were characterized by various spectroscopic methods. The enzymatic assay used showed that these compounds were a suitable DT-diaphorase (NQO1) substrates as evidenced by increasing enzymatic conversion rates relative to that of streptonigrin. Hybrids were tested in vitro against a panel of human cell lines including melanoma, breast, and lung cancers. They showed also a high cytotoxic activity depending on the type of 1,4-quinone moiety and the applied tumor cell lines. It was found that cytotoxic activity of the studied hybrids was increasing against the cell lines with higher NQO1 protein level, such as breast (MCF-7 and T47D) and lung (A549) cancers. Selected hybrids were tested for the transcriptional activity of the gene encoding a proliferation marker (H3 histone), cell cycle regulators (p53 and p21) and the apoptosis pathway (BCL-2 and BAX). The molecular docking was used to examine the probable interaction between the hybrids and NQO1 protein.

Graphical Abstract

1. Introduction

Compounds containing a quinone fragment can be isolated from plants, fungi, and bacteria. Natural substances containing such moiety may have a wide spectrum of biological activities, such as: antimalarial, anticancer, antibacterial, antifungal, antiviral, and antileishmanial. The high biological activity of this group of compounds results from the physicochemical properties of the quinoline moiety, which is a heterocyclic system containing fused benzene and pyridine rings. The pyridine moiety interacts with nucleophilic and electrophilic substituent while the benzene ring creates the hydrophobic interaction. This specific chemical structure allows interaction with many biological targets, such as topoisomerase, protein kinase, telomerase, tubulin, BCl-2 family protein, protein phosphatase Cdc25, oncogenic Ras, thymidylate synthase, the matrix metalloproteinase, and mitotic kinesin-5 [1,2,3,4,5,6,7].
Some of the first compounds with quinoline moiety to be described were quinine and quinidine, which were isolated from cinchona bark (Figure 1). Quinine has been used in malaria treatment, whereas the quinidine exhibits antiarrhythmic properties. The quinoline scaffold is present in many natural and synthetic drugs and plays a major role in their biological activity. For example, chloroquine and mefloquine are used in antimalarial therapy, topotecan in cancer chemotherapy, and ciprofloxacin in bacterial infections [8,9,10,11].
Quinoline compounds constitute a large group of substances, which are classified according to their structural modifications [5]. For example, natural, such as streptonigrin, and synthetic 5,8-quinolinedione compounds show wide spectrum of biological activities such as anticancer, antibacterial, and antiviral. The activity depends on the substituent at the positions C-6, C-7 and C-2 of the 5,8-quinolinedione moiety (Figure 1) [12,13,14,15,16].
Studies on the mechanism of their biological activity showed that they activate the enzyme DT-diaphorase (NQO1), which is a flavoprotein enzyme localized in cytosol (>90%), mitochondria, endoplasmic reticulum and nucleus [17,18,19,20]. The high level of NQO1 protein was established in many human solid tumors found in breast, lung, colon and brain [21,22]. The NQO1 enzyme catalyzes the reduction in the quinone moiety to a hydroquinone using the NADH or NADPH as cofactors. As a side product, reactive oxygen species (ROS) are formed, which cause mutation of DNA [23,24,25].
In this paper, we describe a new hybrid compounds containing 1,4-quinone and quinoline moieties connected by an oxygen atom (Figure 1). We assume, that the combination of two active moieties may result in the increased activity and better bioavailability of resulting product. New hybrids were tested as substrate for the NQO1 protein. Their anticancer activities were assessed against a six human cancer cell lines. For the selected compounds the molecular mechanism of activity was evaluated. Furthermore, the molecular docking study was used to examine the interaction between hybrids and the NQO1 enzyme.

2. Results and Discussion

2.1. Chemistry

The general pathway for preparing the 2-substituted derivatives 3–6 from commercially available quinolin-8-ol 1 and 2-methyl-8-hydroxyquinoline 2 is presented in Scheme 1. The 2-amine derivatives 5–6 were obtained in a multistep procedure. First, compound 1 was converted to 2-chloro-8-hydroxyquinoline according to the literature procedure [26]. The target molecules 5–6 were obtained in the condensation reaction between compound 4 and pyrrolidine or morpholine. The quinoline-2-carbaldehyde 3 was obtained by oxidation of 2-methyl-8-hydroxyquinoline 2 with selenium (IV) oxide [27]. The chemical structures of compounds 3–6 were confirmed by spectroscopic (1H and 13C NMR) methods.
In our previous research, we described the effective method for the synthesis of 5,8-quinolinedione connected to the alkoxyl, alkenyl, enediyne and betulin subunits [14,15,28,29]. This method was used to synthesize hybrid 1,4-quinone with quinoline derivatives. As substrates three different dichloro derivatives of 5,8-quinolinedione (7–9) and 1,4-naphthoquinone (10) were used.
As seen in Scheme 2, compounds 1–6 were connected to 1,4-quinone derivatives 7–10 in the reaction with potassium carbonate and tetrahydrofuran (THF).
After purification, hybrids 11–14 were obtained with a yield of 47–94%. The structures of all new compounds 11–14 were confirmed by 1H NMR, 13C NMR, and HR-MS spectroscopic methods.

2.2. Biological Activity

2.2.1. Enzymatic Assay

The interaction between 1,4-quinone moiety of hybrid and NQO1 protein leads to reduction in quinone to hydroquinone and production of reactive oxide form (ROS) [30,31]. According to a literature method, the ability of hybrids 11–14 and streptonigrin (ST) to be a substrate for NQO1 was examined by measuring the oxidation of NADPH to NADP+ [29,32]. The results are presented in Figure 2 and in Table S1.
Most of the tested compounds show higher enzymatic conversion rate of NQO1 than streptonigrin (ST) (725 μmol NADPH/μmol NQO1/min), indicating that they are suitable substrates for NQO1.
In the group of 5,8-quinolinedione compounds 11a–f, the 11a exhibits the highest enzymatic conversion rate, which is about 2-times higher than streptonigrin. Introduction of methyl group at the C-2 position of the 5,8-quinolinedione moiety (12a–f) has a negligible influence on conversion rates, except 11c and 11e, which are 2.5-and 1.8-times more active than 12c and 12e, respectively. Comparing the activities of 5,8-quinolinedione compounds (11a–f) and 5,8-isoquinolinedione hybrids (13a–f) shows that replacement of nitrogen atom from N-1 to N-2 position decreases the enzymatic conversion rates. The same correlation is observed for 5,8-quinolinedione (11a–f) and 1,4-naphthoquinone (14a–f) derivatives. In the group of hybrids with quinolin-8-yloxy and 2-methylquinolin-8-yloxy substituents (11a–b, 12a–b, 13a–b and 14a–b), the NQO1 activity depends on the type of 1,4-quinone moiety and the order is as follows: 2-methyl-5,8-quinolinedione > 5,8-quinolinedione > 1,4-naphthoquinone > 5,8-isoquinolinedione.
It has been found that the substituent at the C-2 position of quinoline moiety influences the enzymatic conversion rates. Compounds with hydrogen atom (11a, 12a, 13a and 14a) and methyl group (11b, 12b, 13b and 14b) at this position exhibit comparable activities. The oxidation of methyl (11b, 12b, 13b, and 14b) to carboxy (11c, 12c, 13c, and 14c) group decreases the conversion rates. Replacement of chloride atom (11d, 12d, 13d, and 14d) with amine substituent (11e–f, 12e–f, 13e–f, and 14e–f) leads also to reduction in NQO1 activity.

2.2.2. Anticancer Activity

Anticancer activity of compounds 11–14 was designated against following human cancer cell lines: melanoma (Colo-829), ovarian cancer (SK-OV-3), breast cancer (MDA-MB-231, T47D and MCF-7), lung cancer (A549) and normal fibroblasts (HFF-1). As a reference substance, the doxorubicin was used. The results are presented in Table 1 as IC50, where IC50 means the concentration of tested compounds (µM) causing the growth inhibition of 50% for given tumor cells. The negative value (Neg.) means that the IC50 is higher than 30 µM. Selectivity index (SI) as the ratio of the IC50 for normal fibroblast (HFF-1) to IC50 of the corresponding cell line, is presented in Table S2.
Most of the tested hybrids show lower activity than doxorubicin against all cancer cell lines. In the series of tested compounds 11–14, the 1,4-naphthoquinone derivatives (14a–f) show the lowest activity. Analysis of the structure-activity relationship indicates that the activity depends on the type of 1,4-quinone moiety, what means that the nitrogen atom is necessary to preserve the anticancer effect (Table 1).
As seen in Table 1, hybrids 11–14 exhibit the lowest activity against the melanoma cell line (Colo-829). The highest activity against the melanoma cell line is seen for the 6-chloro-7-(quinolin-8-yloxy)isoquinoline-5,8-dione (13a) for which the IC50 is equal to 0.17 µM.
Comparing the activity of 5,8-quinolinedione compounds (11a–f) against the ovary (SK-OV-3) cell line shows that the introduction of a substituent at the C-2 position of quinoline moiety (11b) causes an increase in activity. The replacement of a chlorine atom (11d) with an amine substituent (11e–f) leads to a decrease in activity.
The breast cancer cells lines used for testing have different immunoprofile classes. Two of them (T47D and MCF-7) belong to Luminal A, while MDA-MB-231 to the Claudin-low class. According to literature, the Luminal A cell line subtype is less aggressive than the Claudin-low class [33]. Most hybrids 11–14 exhibit higher activity against Claudin-low class cells (MDA-MB-231) than Luminal A class cell lines (T47D and MCF-7). The activity against the MDA-MB-231 cell line depends on the type of 1,4-quinone moiety and the order is as follows: 5,8-isoquinolinedione > 2-methyl-5,8-quinolinedione > 5,8-quinolinedione > 1,4-naphthoquinone. Comparing the IC50 value against T47D and MCF-7 shows that compounds 11–13 exhibit comparable activity. Important feature is observed for 1,4-naphthoquinone hybrids 14a–f, which exhibit low activity against MCF-7 and no effect against T47D.
The cell lines used in the research have different expression levels of a gene encoding NQO1 protein. According to literature, the cell lines are classified into six categories depending on the level of RNA expression denoted as the normalized transcript expression values (nTPM). The A549 line belongs to the enhanced (nTPM = 2724.0) while T47D and MCF-7 belong to low specificity lines (nTPM in the range of 725.9–631.3). For the other lines the nTPM values were not detected [34,35].
From this perspective, hybrids 11–14 exhibit the higher activity against cancer cell line with enhanced level of gene encoding NQO1 enzyme. Most of the tested hybrids exhibit the highest activity against the A549 cell line. The exception is compound 11e, which is almost 6-times more active against MCF-7 than A549. Therefore, the effect depends on the nTPM for each line and the order is as follows: A549 > MCF-7 > T47D.
Hybrids with 5,8-quinolinedione (11a–f and 12a–f) and 5,8-isoquinolinedione (13a–f) moieties exhibit higher activity than compounds with 1,4-naphthoquinone (14a–f) against the lung cancer cell line (A549). In general, for this group of compounds, it can be seen that position of nitrogen atom in 5,8-quinolinedione moiety influences anticancer effect. Hybrids with the 5,8-isoquinolinedione moiety (13a–f) are characterized by the highest anticancer effect. For compounds 12a–f, the introduction of the methyl group at the C-2 position of the 5,8-quinolinedione moiety affects their cytotoxicity showing that most of them have higher activity than compounds 11a–f against lung(A549) cell line.
The second important aspect affecting the activity is the substituent at the C-2 position of the quinolinoxy moiety. Generally, a trend is that the introduction of methyl group (11b, 12b, 13b and 14b) decreases the cytotoxicity. However, the oxidation of methyl group (11b, 12b, 13b and 14b) to the carbonyl group (11c, 12c, 13c and 14c) reduces the activity against the A549 line. The replacement of methyl group with chlorine atom (11d, 12d, 13d and 14d) significantly increases activity. The amine substituent (11e–f, 12e–f, 13e–f and 14e–f) shows little effect on activity. In the series of 5,8-isoquinolinediones (13a–f) the activity depends on a group at the C-2 position of quinolinoxy moiety and the order is as follows: hydrogen (13a) > chloride (13d) > methyl (13b) > carbonyl (13c) > morpholinyl (13f) > piperidin-1-yl (13e).
The hybrids 11–14 show less cytotoxicity against normal fibroblast cell line (HFF-1) than doxorubicin. However, no correlation was observed between the type of 1,4-quinone moiety and the cytotoxicity of the compound (Table 1).
Most of tested hybrids 11–14 show higher selectivity index than doxorubicin (SI = 6.00) against the A549 cell line. However, the highest SI index was obtained for 13a and 13d, reaching values of 923.00 and 184.83, respectively.

2.2.3. Apoptosis Analysis

The mechanism of anticancer activity was determined by detection of transcriptional activity of the genes encoding a proliferation marker (H3 histone), cell cycle regulators (p53 and p21), and the mitochondrial apoptosis pathway (BCL-2 and BAX) (Figure 3a–d). The derivatives 11b, 12b, 13b, and 14b were selected for this study. The research was carried out after 24 h of exposure of the A549 cell line to the compounds under study (at a concentration equal to half of IC50).
The tested compounds cause a decrease in the number of mRNA copies of the histone H3 gene. The highest effect is observed for compounds 13b and 14b, which reduce the amount of mRNA copies by half. These results suggest that the activity against A549 cells could be related to the inhibition of cell proliferation (Figure 3a).
The interaction of hybrids with the NQO1 protein leads to the production of reactive oxygen species (ROS). The increased concentration of ROS can damage many biological structures such as proteins, lipids, and nucleic acids. The TP53 is a suppressor gene that prevents transmission of genetic disorders in newly formed cells [36,37]. As seen in Figure 3b, the tested hybrids generate a change in expression of the TP53. Compounds with the 5,8-quinolinedione (11b and 12b) and 5,8-isoquinolinedione (13b) moieties show significant increase in the TP53 gene expression. However, the type of 5,8-quinolinedione moiety has no effect on the TP53 gene expression. Hybrid 14b containing the 1,4-naphthoquinone moiety causes a slight increase in expression of this gene.
The TP35 gene encodes the p53 protein, which controls the expression of many genes involved in the apoptosis pathway. One of these genes is CDKN1A, which codes for the p21 protein involved in cell cycle arrest in the G1 phase [38,39,40]. The highest increase in copies of mRNA is observed for 13b, whereas the 14b causes a slight effect on expression of CDKN1A in lung cancer (A549) (Figure 3c). Summarizing, the nitrogen atom at 1,4-quinone moiety is necessary for activation of TP53 and CDKN1A genes.
The p53 protein affects the expression of the BCL-2 protein family. The BCL-2 family includes both pro-apoptotic (BAX) and anti-apoptotic (BCL-2) proteins [41]. Figure 3d shows the BAX and BCL-2 of mRNA copies for the tested compounds and the control. A comparison of the BAX/BCL-2 ratio of mRNA copies for the control and tested compounds show that hybrids activate the mitochondrial apoptosis pathway.

2.3. Molecular Docking Study

Enzymatic studies show that hybrids are a suitable substrate for the NQO1 enzyme. The molecular docking study was used to examine the possible interaction between hybrids (11–14) and NQO1 protein. The NQO1 protein was obtained from PDB (PDB ID:2F1O) as a complex with the flavin adenine dinucleotide (FAD) cofactor. As a reference substance, streptonigrin (ST) was used. The scoring function of the tested compounds and streptonigrin is presented in Table 2. The lowest scores of the binding energy (kcal/mol) of protein-ligand complexes correspond to a strong binding affinity and the most probable ligand-protein system.
Compared to streptonigrin (ST), hybrids show lower binding energy with NQO1, which means that these complexes are more stable. Analysis of the scoring values shows that ligands with 5,8-quinolinedione (11a–f and 12a–f) and 5,8-isoquinolinedione (13a–f) moieties are bonded to the active site of the protein more strongly than in the case of 1,4-naphthoquinone (14a–f) hybrids. However, the type of 5,8-quinolinedione moiety slightly influences the scoring value. This result is consistent with the NQO1 enzymatic study.
As seen in Figure 4, the hybrids are localized in a hydrophobic matrix of the active enzyme site. The 1,4-quinolinedione moiety is located near the FAD cofactor and side chains of aromatic residue in positions Tyr128, Trp105, and Phe178.
For the selected hybrids 11b, 12b, 13b, and 14b, complete models of the interaction in 2D (Figure 5) and 3D (Figure S1) views are presented. Details of the type and length of binding between ligands and enzyme residues are summarized in Table S3.
In tested hybrids containing the 1,4-quinone moiety, the carbonyl atom creates the hydrogen bond with the hydroxy group of tyrosine (TYR128) and hydrophobic interaction with phenylalanine (PHE178), tryptophan (TRP105), histidine (HIS161), methionine (MET154) and a FAD cofactor (Figure 5a–d). Furthermore, in compounds 11b and 13b, the oxygen atom at the C-7 position of 5,8-quinolinedione moiety creates a weak hydrogen bond with the CH2 group of glycine (GLY149) (Figure 5a,c). The quinolinoxy group in ligands (11b, 12b, 13b, and 14b) creates the hydrophobic interaction with tyrosine (TYR128) (Figure 5a–d). For hybrid 14b, the hydrophobic interaction with phenylalanine was additionally observed (Figure 5d).
It was found that derivative 12b shows the highest enzymatic activity among all tested compounds. This effect may be due to the hydrophobic interaction between the methyl group at the C-2 position of the 5,8-quinolinedione moiety and the FAD cofactor (Figure 5b).

3. Materials and Methods

3.1. Chemistry

The nuclear magnetic resonance (NMR) spectra were performed using the Bruker Avance 600 spectrometer (Bruker, Billerica, MA, USA) in CDCl3 or DMSO-d6 solvents. Chemical shifts (δ) are reported in ppm and J values in Hz. Multiplicity is designated as singlet (s), board singlet (bs), doublet (d), doublet of doublets (dd), and multiplet (m). High-resolution mass spectral analysis (HR-MS) was performed using the Bruker Impact II instrument (Bruker, Billerica, MA, USA). Calculation of the theoretical molecular mass for compounds was performed using “The Exact Mass Calculator, Single Isotope Version” (Available online: http://www.sisweb.com/referenc/tools/exactmass.htm; Ringoes, NJ, USA)) (accessed on 10 September 2022). Melting points were measured by the Electrothermal IA 9300 melting point apparatus. A microwave reactor (Discover SP-D, CEM Corporation, Matthews, NC, USA) was used in the synthesis of 2-aminoquinolin-8-ols.
The 8-hydroxyquinoline-2-carbaldehyde 3 and 2-chloroquinolin-8-ol 4 were prepared according to the method described in the literature [26,42].
The 1,4-quinones 7–9 were obtained according to literature methods [12,43]. The 2,3-dichloro-1,4-naphthoquinon 10 was purchased in Merck (Darmstadt, German).
  • Synthesis of 2-aminoquinolin-8-ols 5–6
The 2-chloroquinolin-8-ol 4 (0.3 g; 1.55 mmol) was added to 3 mmol of amine (piperidine or morpholine). The reaction vessel was placed in a microwave reactor, and the reaction was carried out for 10 min at a temperature of 110 °C at a maximum wave power (300 W). After cooling, the reaction mixture was diluted with methylene chloride (10 mL) and washed with 15 mL of water. The obtained organic layer was dried with magnesium sulfate and concentrated with a vacuum evaporator. The crude product was purified by column chromatography (SiO2, chloroform/ethanol, 15:1, v/v) to give pure products 5–6.
2-(piperidin-1-yl)quinolin-8-ol (5): 0.21 g (0.127 mmol); yield 60%; oil. The spectral data were confirmed by literature [44].
2-morpholinoquinolin-8-ol (6): 0.28 g (0.127 mmol); yield 80%; oil. The spectral data were confirmed by literature [44].
  • Synthesis of hybrids 11–14
The 1,4-quinone compounds 7–10 (0.44 mmol), quinoline-8-ol derivatives 1–6 (0.44 mmol) and potassium carbonate (0.061 g, 0.44 mmol) were dissolved in tetrahydrofuran. After 24 h at room temperature, the reaction mixture was concentrated with a vacuum evaporator. The crude product was purified by column chromatography (SiO2, chloroform/ethanol, 15:1, v/v) to give pure products 11–14.
6-chloro-7-(quinolin-8-yloxy)quinoline-5,8-dione (11a): 0.086 g (0.256 mmol); Yield 58%; mp 112–114 °C; 1H NMR (DMSO-d6, 600 MHz) δ 7.46 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.73 (dd, J = 4.2 Hz, J = 8.4 Hz, 1H), 7.99 (dd, J = 4.2 Hz, J = 7.8 Hz, 1H), 8.48 (dd, J = 1.8 Hz, J = 7.8 Hz, 1H), 8.53 (dd, J = 1.8 Hz, J = 7.8 Hz, 1H), 8.99 (dd, J = 1.8 Hz, J = 4.2 Hz, 1H), 9.17 (dd, J = 1.8 Hz, J = 4.8 Hz, 1H), 10.48 (bs, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 117.6, 120.7, 123.3, 128.6, 129.0, 129.4, 129.5, 135.3, 136.7, 138.8, 143.8, 144.5, 147.6, 149.1, 151.3, 155.0, 176.6, 181.5; HRAPCIMS m/z 337.0338 (calcd for C18H9ClN2O3, 337.0379) (Figure S2).
6-chloro-7-[(2-methylquinolin-8-yl)oxy]quinoline-5,8-dione (11b): 0.105 (0.300 mmol); yield 68%; mp 110–112 °C; 1H NMR (DMSO-d6, 600 MHz) δ 2.74 (s, 3H), 7.32 (d, J = 8.4 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 7.55 (dd, J = 4.2 Hz, =8.4 Hz, 1H), 7.99 (dd, J = 4.2 Hz, J = 7.8 Hz, 1H), 8.30 (dd, J = 1.2 Hz, J = 7.8 Hz, 1H), 8.47 (dd, J = 1.8 Hz, J = 7.8 Hz, 1H), 9.12 (dd, J = 1.8 Hz, J = 4.8 Hz, 1H), 9.88 (bs, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 25.2, 114.8, 117.5, 124.0, 127.7, 128.7, 129.5, 130.5, 130.8, 131.2, 135.3, 144.5, 147.6, 155.0, 157.9, 176.6, 181.5. HRAPCIMS m/z 351.0549 (calcd for C19H11ClN2O3, 351.0536) (Figure S3).
8-[(6-chloro-5,8-dioxo-5,8-dihydroquinolin-7-yl)oxy]quinoline-2-carbaldehyde (11c): 0.127 g (0.348 mmol); yield 79%; mp 168–170 °C; 1H NMR (CDCl3, 600 MHz) δ 7.46 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.82 (dd, J = 4.2 Hz, J = 8.4 Hz, 1H), 8.09 (d, J = 1.2 Hz, 1H), 8.19 (dd, J = 4.2 Hz, J = 7.8 Hz, 1H), 8.35 (dd, J = 1.2 Hz, J = 7.8 Hz, 1H), 8.56 (dd, J = 1.8 Hz, J = 7.8 Hz, 1H), 9.17 (dd, J = 1.8 Hz, J = 4.8 Hz, 1H), 10.25 (s, 1H); 13C NMR (CDCl3, 150 MHz) δ 116.4, 121.6, 126.9, 127.3, 129.6, 131.0, 137.4, 139.0, 142.5, 148.7, 158.2, 159.0, 162.9, 178.0, 181.9, 190.1; HRAPCIMS m/z 365.0351 (calcd for C19H9ClN2O4, 365.0329) (Figure S4).
6-chloro-7-[(2-chloroquinolin-8-yl)oxy]quinoline-5,8-dione (11d): 0.103 g (0.278 mmol); yield 63%; mp 123–125 °C; 1H NMR (CDCl3, 600 MHz) δ 7.64 (d, J = 9.0 Hz, 1H), 7.80 (m, 2H), 7.95 (dd, J = 4.2 Hz, J = 7.8 Hz, 1H), 8.33 (d, J = 8.4 Hz, 1H), 8.44 (d, J = 8.4, 1H), 8.65 (dd, J = 1.8 Hz, J = 7.8 Hz, 1H), 9.15 (dd, J = 1.8 Hz, J = 4.8 Hz, 1H); 13C NMR (CDCl3, 150 MHz) δ 111.6, 116.4, 123.0, 127.1, 128.3, 128.8, 129.8, 131.3, 135.5, 144.6, 147.5, 148.6, 155.1, 158.6, 176.4, 181.8; HRAPCIMS m/z 371.0019 (C18H8Cl2N2O3, 370.999) (Figure S5).
6-chloro-7-{[2-(pyrrolidin-1-yl)quinolin-8-yl]oxy}quinoline-5,8-dione (11e): 0.159 g (0.392 mmol); yield 89%; oil; 1H NMR (CDCl3, 600 MHz) δ 2.10 (bs, 4H), 3.67 (bs, 4H), 6.85 (d, J = 9.6 Hz, 1H), 7.05 (m, 2H), 7.27 (d, J = 8.4 Hz, 1H), 7.75 (dd, J = 4.2 Hz, J = 8.4 Hz, 1H), 7.94 (dd, J = 4.2 Hz, J = 7.8 Hz, 1H), 8.53 (dd, J = 1.8 Hz, J = 7.8 Hz, 1H), 9.11 (dd, J = 1.8 Hz, J = 4.8 Hz, 1H); 13C NMR (CDCl3, 600 MHz) δ 24.4, 45.7, 110.9, 116.8, 121.5, 127.0, 127.2, 128.0, 128.2, 134.4, 143.0, 143.9, 146.2, 153.8, 175.6, 179.9; HRAPCIMS m/z 406.0967 (calcd for C22H16ClN3O3, 406.0958) (Figure S6).
6-chloro-7-{[2-(morpholin-4-yl)quinolin-8-yl]oxy}quinoline-5,8-dione (11f): 0.175 g (0.414 mmol); yield 94%; oil; 1H NMR (DMSO-d6, 600 MHz) δ 3.73 (m, 4H), 3.76 (m, 4H), 7.04 (d, J = 8.4 Hz, 1H), 7.31 (dd, J = 4.2 Hz, J = 8.4 Hz, 1H), 7.94 (dd, J = 4.2 Hz, J =7.8 Hz, 1H), 8.11 (d, J = 9.0 Hz, 1H), 8.45 (dd, J = 1.8 Hz, J = 7.8 Hz, 1H), 9.11 (dd, J = 1.8 Hz, J = 4.8 Hz, 1H), 9.14 (bs, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 25.1, 45.1, 111.4, 115.8, 117.3, 123.5, 123.7, 129.0, 129.5, 135.3, 137.3, 138.0, 144.3, 144.2, 147.6, 148.6, 155.0, 156.8, 176.7, 181.6; HRAPCIMS m/z 422.0941 (calcd for C22H16ClN3O4, 422.0908) (Figure S7).
6-chloro-2-methyl-7-(quinolin-8-yloxy)quinoline-5,8-dione (12a): 0.071 g (0.202 mmol); yield 49%; mp 115–117 °C; 1H NMR (DMSO-d6, 600 MHz) δ 2.72 (s, 3H), 7.79 (m, 2H), 8.16 (d, J = 8.4 Hz, 1H),8.33 (d, J = 8.4 Hz, 1H), 8.46 (d, J = 7.8 Hz, 1H), 8.67 (dd, J = 1.8 Hz, J = 7.8 Hz, 1H), 9.14 (dd, J = 1.8 Hz, J = 4.8 Hz, 1H), 10.38 (bs, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 25.1, 115.8, 120.7, 123.6, 127.8, 128.7, 135.1, 137.6, 146.9, 155.4, 164.2, 178.7, 180.9; HRAPCIMS m/z 351.0539 (calcd. for C19H11ClN2O3, 351.0536) (Figure S8).
6-chloro-2-methyl-7-[(2-methylquinolin-8-yl)oxy]quinoline-5,8-dione (12b): 0.078 (0.215 mmol); yield 52%; mp 130–132 °C; 1H NMR (DMSO-d6, 600 MHz) δ 2.71 (s, 3H), 2.79 (s, 3H), 7.66 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 8.42 (d, J = 7.8 Hz, 1H), 8.50 (d, J = 8.4 Hz, 1H), 10.40 (bs, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 25.0, 25.4, 119.6, 122.5, 123.8, 124.2, 127.5, 127.9, 128.6, 135.1, 136.0, 137.5, 148.4, 151.3, 154.6, 161.0, 173.3, 181.0; HRAPCIMS m/z 365.0699 (calcd. for C20H13ClN2O3, 365.0693) (Figure S9).
8-[(6-chloro-2-methyl-5,8-dioxo-5,8-dihydroquinolin-7-yl)oxy]quinoline-2-carbaldehyde (12c): 0.116 g (0.306 mmol); yield 74%; mp 184–186 °C; 1H NMR (DMSO-d6, 600 MHz) δ 2.73 (s, 3H), 7.81 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 8.23 (d, J = 8.4 Hz, 1H), 8.27 (d, J = 8.4 Hz, 1H), 8.45 (d, J = 1.8 Hz, 1H) 8.46 (d, J = 7.8 Hz, 1H), 8.90 (d, J = 8.4 Hz, 1H), 10.29 (s, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 25.0, 113.2, 119.3, 123.4, 127.8, 128.0, 131.0, 135.2, 139.5, 148.4, 153.2, 162.8, 164.3, 173.3, 180.8, 193.8; HRAPCIMS m/z 379.0491 (calcd. for C20H11ClN2O4, 379.0486) (Figure S10).
6-chloro-2-methyl-7-[(2-chloroquinolin-8-yl)oxy]quinoline-5,8-dione (12d): 0.092 g (0.240 mmol); yield 58%; mp 120–122 °C; 1H NMR (CDCl3, 600 MHz) δ 2.86 (s, 3H), 7.63 (m, 2H), 7.94 (m, 2H), 8.32 (d, J = 8.4 Hz, 1H), 8.44 (d, J = 8.4 Hz, 1H), 8.52 (d, J = 7.8 Hz, 1H); 13C NMR (CDCl3, 150 MHz) δ 25.3, 115.0, 116.3, 121.5, 124.1, 127.6, 130.5, 135.2, 139.3, 143.3, 144.4, 151.8, 158.3, 161.1, 178.1, 180.1; HRAPCIMS m/z 385.0159 (caldc. for C19H10Cl2N2O3, 385.0147) (Figure S11).
6-chloro-2-methyl-7-{[2-(pyrrolidin-1-yl)quinolin-8-yl]oxy}quinoline-5,8-dione (12e): 0.144 g (0.343 mmol); yield 83%; oil; 1H NMR (DMSO-d6, 600 MHz) δ 1.99 (bs, 4H), 2.72 (s, 3H), 3.60 (bs, 4H), 6.97 (m, 2H), 7.25 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 8.34 (d, J = 8.4 Hz, 1H), 8.78 (bs, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 25.1, 47.1, 115.2, 117.5, 122.2, 127.4, 128.6, 128.6, 135.4, 137.4, 137.8, 143.9, 144.1, 147.0, 148.0, 154.8, 164.7, 176.8, 181.6; HRAPCIMS m/z 420.1125 (calcd. for C23H18ClN3O3, 420.1114) (Figure S12).
6-chloro-2-methyl-7-{[2-(morpholin-4-yl)quinolin-8-yl]oxy}quinoline-5,8-dione (12f): 0.164 g (0.376 mmol); yield 91%; oil; 1H NMR (DMSO-d6, 600 MHz) δ 2.72 (s, 3H), 3.21 (m, 4H), 3.74 (m, 4H), 7.03 (d, J = 8.4, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 8.11 (d, J = 8.4 Hz, 1H), 9.12 (bs, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 25.1, 45.6, 110.9, 117.3, 123.5, 123.7, 126.4, 127.4, 128.6, 129.9, 135.4, 137.3, 138.0, 138.5, 144.1, 147.0, 148.6, 156.8, 164.7, 176.7, 181.6; HRAPCIMS m/z 436.1076 (calcd. for C23H18ClN3O4, 436.1064) (Figure S13).
6-chloro-7-(quinolin-8-yloxy)isoquinoline-5,8-dione (13a): 0.073 g (0.216 mmol); yield 49%; mp 86–88 °C; 1H NMR (DMSO-d6, 150 MHz) δ 7.59 (m, 1H), 7.88 (dd, J = 4.8 Hz, J = 8.4 Hz, 1H), 8.05 (d, J = 8.4 Hz, 1H), 8.33 (m, 2H), 9.10 (m, 2H), 9.47 (s, 1H); 9.49 (s, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 117.8, 119.8, 122.0, 124.2, 126.1, 128.3, 128.5, 130.7, 133.6, 135.9, 147.3, 150.3, 154.9, 179.5; HRAPCIMS m/z 337.0379 (calcd. for C18H9ClN2O3, 337.0379) (Figure S14).
6-chloro-7-[(2-methylquinolin-8-yl)oxy]isoquinoline-5,8-dione (13b): 0.080 g (0.228 mmol); yield 52%, mp 110–112 °C; 1H NMR (CDCl3, 600 MHz) δ 2.97 (s, 3H), 7.57 (dd, J = 1.2 Hz, J = 8.4 Hz, 1H), 9.93 (d, J = 4.8 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 8.30 (dd, J = 7.8 Hz, J = 8.4 Hz, 1H), 8.39 (d, J = 8.4 Hz, 1H), 9.18 (d, J = 4.8 Hz, 1H), 9.55 (s, 1H), 9.58 (s, 1H); 13C NMR (CDCl3, 150 MHz) δ 24.4, 118.7, 119.0, 122.9, 123.7, 124.8, 125.9, 126.6, 130.3, 132.4, 136.1, 137.5, 146.2, 154.6, 159.8, 176.2, 180.0; HRAPCIMS m/z 351.0553 (calcd. for C19H11ClN2O3, 351.0536) (Figure S15).
8-[(6-chloro-5,8-dioxo-5,8-dihydroisoquinolin-7-yl)oxy]quinoline-2-carbaldehyde (13c): 0.111 g (0.299 mmol); yield 68%; mp 166–168 °C; 1H NMR (CDCl3, 600 MHz) δ 8.04 (m, 2H), 8.17 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.50 (m, 2H), 9.21 (d, J = 4.8 Hz, 1H), 9.56 (s, 1H), 10.41 (s, 1H); 13C NMR (CDCl3, 150 MHz) δ 111.3, 119.0, 119.3, 123.3, 123.6, 125.0, 125.6, 127.1, 131.0, 136.7, 138.1, 148.7, 152.8, 153.1, 156.3, 173.5, 180.9, 193.0; HRAPCIMS m/z 365.0317 (calcd. for C19H9ClN2O4, 365.0329) (Figure S16).
6-chloro-7-[(2-chloroquinolin-8-yl)oxy]isoquinoline-5,8-dione (13d): 0.098 g (0.269 mmol); yield 61%; mp 127–129 °C; 1H NMR (CDCl3, 600 MHz) δ 7.64 (d, J = 9.0 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 8.17 (m, 2H), 8.34 (d, J = 8.4 Hz, 1H), 8.46 (d, J = 8.4 Hz, 1H), 9.19 (d, J = 4.8 Hz, 1H), 9.54 (s, 1H); 13C NMR (CDCl3, 150 MHz) δ 28.7, 118.5, 120.4, 122.4, 123.5, 124.0, 124.9, 125.8, 127.0, 135.2, 137.4, 138.3, 147.2, 150.5, 152.4, 154.5, 179.7; HRAPCIMS m/z 371.006 (calcd. for C18H8Cl2N2O3, 370.999) (Figure S17).
6-chloro-7-{[2-(pyrrolidin-1-yl)quinolin-8-yl]oxy}isoquinoline-5,8-dione (13e): 0.150 g (0.370 mmol); yield 84%; oil; 1H NMR (CDCl3, 600 MHz) δ 2.10 (bs, 4H), 3.65 (bs, 4H), 6.85 (d, J = 8.4 Hz, 1H), 7.03 (d, J = 7.8 Hz, 1H), 7.27 (d, J = 8.4 Hz, 1H), 7.93 (dd, J = 7.8 Hz, 1H), 7.98 (d, J = 5.4 Hz, 1H), 8.04 (d, J = 5.4 Hz, 1H), 9.14 (dd, J = 5.4 Hz, J = 8.4 Hz, 1H), 9.46 (s, 1H); 13C NMR (CDCl3, 150 MHz) δ 25.5, 45.1, 112.0, 118.9, 119.2, 122.5, 124.8, 127.1, 130.2, 136.5, 144.0, 144.8, 149.5, 155.4, 177.9, 181.0; HRAPCIMS m/z 406.0959 (calcd. for C22H16ClN3O3, 406.0958) (Figure S18).
6-chloro-7-{[2-(morpholin-4-yl)quinolin-8-yl]oxy}isoquinoline-5,8-dione (13f): 0.165 g (0.391 mmol); yield 89%; oil; 1H NMR (DMSO-d6, 600 MHz) δ 3.79 (m, 8H), 7.06 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 4.8 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H), 8.36 (bs, 1H), 9.20 (d, J = 4.8 Hz, 1H), 9.30 (s, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 27.9, 45.6, 110.9, 111.5, 115.7, 117.4, 119.3, 123.5, 123.7, 125.3, 137.2, 138.01, 143.4, 145.1, 148.5, 156.8, 178.0, 181.5; HRAPCIMS m/z 422.0922 (calcd. for C22H16ClN3O4, 422.0908) (Figure S19).
2-chloro-3[(quinolin-8-yl)oxy]naphthalene-1,4-dione (14a): 0.093 g (0.278 mmol); yield 63%; mp 115–117 °C; 1H NMR (DMSO-d6, 600 MHz) δ 7.80 (dd, J = 4.2 Hz, J = 7.8 Hz, 1H), 7.97 (m, 2H), 8.16 (d, J = 9.0 Hz, 1H), 8.22 (m, 2H), 8.34 (d, J = 8.4 Hz, 1H), 8.67 (dd, J = 1.8 Hz, J = 9.0 Hz, 1H), 9.13 (dd, J = 1.8 Hz, J = 3.6 Hz, 1H), 10.24 (bs, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 120.7, 121.1, 122.6, 122.7, 123.6, 127.1, 127.6, 129.2, 131.1, 132.3, 132.8, 133.5, 134.9, 137.5, 145.0, 152.0, 154.2, 181.8, 182.7; HRAPCIMS m/z 336.0431 (calcd. for C19H10ClNO3, 336.0427) (Figure S20).
2-chloro-3-[(2-methylquinolin-8-yl)oxy]naphthalene-1,4-dione (14b): 0.072 g (0.207 mmol); yield 47%; mp 100–102 °C; 1H NMR (DMSO-d6, 600 MHz) δ 2.85 (s, 3H), 7.72 (d, J = 8.4 Hz, 1H), 8.01 (m, 2H), 8.13 (d, J = 8.4 Hz, 1H), 8.26 (m, 2H), 8.28 (m, 2H), 8.57 (d, J = 8.4 Hz, 1H); 13C NMR (DMSO-d6, 150 MHz) δ 25.4, 119.7, 122.7, 124.5, 124.2, 126.9, 127.0, 127.4, 127.5, 132.8, 133.5, 134.9, 136.0, 136.1, 137.5, 154.1, 160.9, 181.8; HRAPCIMS m/z 350.0595 (calcd. for C20H12ClNO3, 350.0584) (Figure S21).
8-[(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)oxy]quinoline-2-carbaldehyde (14c): 0.120 g (0.330 mmol); yield 75%; mp 131–133 °C; 1H NMR (CDCl3, 600 MHz) δ 7.87 (m, 2H), 8.02 (d, J = 8.4 Hz, 1H), 8.26 (d, J = 8.4 Hz, 1H), 8.33 (m, 2H), 8.37 (m, 1H), 8.55 (d, J = 7.8 Hz, 1H), 8.59 (d, J = 9.0 Hz, 1H), 10.42 (s, 1H); 13C NMR (CDCl3, 150 MHz) δ 118.9, 123.7, 124.7, 126.6, 127.0, 127.3, 130.9, 132.6, 133.3, 134.4, 136.8, 138.1, 152.9, 154.1, 174.6, 181.5, 193.2; HRAPCIMS m/z 364.0350 (calcd. for C20H10ClNO4, 364.0377) (Figure S22).
2-chloro-3-[(2-chloroquinolin-8-yl)oxy]naphthalene-1,4-dione (14d): 0.132 g (0.357 mmol); yield 81%; mp 101–103 °C; 1H NMR (CDCl3, 600 MHz) δ 7.67 (m, 2H), 7.89 (d, J = 8.4 Hz, 1H), 7.93 (m, 1H), 7.98 (m, 2H), 8.19 (d, J = 7.2 Hz, 1H), 8.22 (m, 1H), 8.57 (d, J = 8.4 Hz, 1H); 13C NMR (CDCl3, 150 MHz) δ 113.9, 117.1, 123.9, 127.1, 128.0, 128.5, 129.0, 131.0, 131.7, 137.9, 140.9, 149.6, 151.1, 155.3, 178.0, 178.8; HRAPCIMS m/z 370.0040 (calcd. for C19H9Cl2NO3, 370.0038) (Figure S23).
2-chloro-3-{[2-(pyrrolidin-1-yl)quinolin-8-yl]oxy}naphthalene-1,4-dione (14e): 0.148 g (0.366 mmol); yield 83%; oil; 1H NMR (CDCl3, 600 MHz) δ 3.63 (bs, 8H), 7.00 (m, 2H), 7.06 (d, J = 7.8 Hz, 1H), 7.28 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.99 (m, 2H), 8.07 (d, J = 8.4 Hz, 1H), 8.21 (m, 1H); 13C NMR (CDCl3, 150 MHz) δ 25.4, 47.1, 110.1, 117.5, 120.4, 122.3, 122.7, 127.1, 127.3, 131.5, 134.9, 135.3, 137.5, 143.3, 145.2, 147.9, 151.4, 154.8, 178.3, 181.7; HRAPCIMS m/z 405.1022 (calcd. for C23H17ClN2O3, 405.1006) (Figure S24).
2-chloro-3-{[2-(morpholin-4-yl)quinolin-8-yl]oxy}naphthalene-1,4-dione (14f): 0.172 g (0.409 mmol); yield 93%; oil; 1H NMR (DMSO-d6, 600 MHz) δ 3.76 (m, 4H), 3.80 (m, 4H), 7.22 (d, J = 8.4, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.37 (d, J = 9.0 Hz, 1H), 8.00 (m, 2H), 8.08 (m, 1H), 8.15 (d, J = 9.0 Hz, 1H), 8.22 (m, 2H); 13C NMR (DMSO-d6, 150 MHz) δ 27.9, 45.6, 110.8, 117.3, 123.6, 127.1, 127.3, 131.6, 132.1, 134.9, 135.3, 137.2, 138.1, 143.4, 145.2, 148.5, 156.8, 178.3, 181.7; HRAPCIMS m/z 421.0937 (calcd. for C23H17ClN2O4, 421.0955) (Figure S25).

3.2. Biological Activity

3.2.1. Enzymatic Assay

Compounds 11–14 (10 µmol/L) were tested as NQO1 substrates using the NADPH recycling assay according to the literature method [23,45]. The recombinant NQO1 (DT-diaphorase, EC 1.6.5.5, human recombinant, Sigma-Aldrich) was used, and the oxidation of NADPH to NADP+ was measured at the absorption wavelength of 340 nm on the BioTek 800TS microplate reader (BioKom, Janki, Poland). Compounds were dissolved in dimethyl sulfoxide (2 µL) and added to the 96-well plate. The NQO1 protein (1.4 µg/mL) in 50 mmol/L potassium phosphate buffer (pH = 7.4) was added to each well (198 µL) (Nunc Thermo Fisher Scientific, Waltham, MA, USA). Once the 96-well plate was filled with the assay solutions, except the NADPH solution, it was placed into the instrument and left to sit for 5 min before starting the measurements. The enzymatic reaction was initiated by automatically dispensing the NADPH solution into the wells, and data were recorded at 10 s intervals for 5 min at 25 °C. The linear part of the absorbance vs. time graphs (the first 20 s to 1 min) was fitted, and the slopes were calculated. NADPH oxidation rates were compared with reactions lacking the tested compound. Initial velocities were calculated, and data were expressed as µmol NADPH/µmol NQO1/min. All reactions were carried out at least in triplicate.

3.2.2. Anticancer Activity

Compounds 7–14 and doxorubicin were tested for cytotoxic activity in vitro against panel of human cancer cell lines: melanoma (Colo-829, ATCC, Rockville, MD, USA), ovarian cancer (SK-OV-3, ATCC, Rockville, MD, USA), breast cancer (T47D, MCF-7, and MDA-MB-231, ATCC, Rockville, MD, USA) and lung cancer (A549, ATCC, Rockville, MD, USA). The cultured cells were kept at 37 °C and 5% CO2. The cells were seeded (5 × 104 cells/well/100 mL DMEM supplemented with 10% FCS and streptomycin/penicillin) using 96-well plates (Nunc Thermo Fisher Scientific, Waltham, MA, USA). The tested compounds 7–14 with the concentration of 1–100 µg/mL DMSO were inducted with the cancer cells for 72 h. The WST-1-formazan (proliferation reagent WST-1 assay, Roche Diagnostics, Mannheim, Germany) was detected using a microplate reader at 450 nm. Results were expressed as a mean value of at least three independent experiments performed in triplicate.

3.2.3. Apoptotic Assay

Transcriptional activity of genes (TP53, CDKN1A, BAX, and BCL-2) was rated by real-time RT-QPCR using Opticon™ DNA Engine system (MJ Research, Watertown, NY, USA) and QuantTect® SYBR® Green RT-PCR Kit (Qiagen, Hilden, Germany). Cultured cells were incubated with tested compounds for 24 h. RNA was extracted using Quick-RNA™ MiniPrep kit columns (Zymo Research, Irvine, CA, USA). The extracted RNA was assessed qualitatively and quantitatively. The amount and purity of the total RNA in extracts were determined spectrophotometrically (HP8452A apparatus, Hewlett Packard, Waldbronn, Germany).

3.3. Molecular Docking

A molecular docking study was performed using the crystal structure of human NQO1 protein, which was collected from the Protein Data Bank (PDB) database with the PDB identifier 2F1O [46]. During docking, the FAD molecules were presented into binding sites as cofactors.
A molecular docking study was performed with the AutoDock Vina software package [47]. The grid center of Vina docking was selected as the center of reference ligands that accompanied the downloaded protein complexes. The grid size was set to 25 Å × 25 Å × 25 Å, which is large enough to cover the entire target active site. Default values of all other parameters were used, and the complexes were submitted to 8 genetic algorithm runs. All obtained results were visualized using the BIOVIA Discovery Studio software package [48].

3.4. Statistical Analysis

Mann–Whitney U test was used to determine statistical differences between the means, where p < 0.05 was considered to be statistically significant.

4. Conclusions

The combination of 1,4-quinone with a quinoline moiety allowed us to obtain a new class of compounds as potential anticancer agents. The enzymatic assay showed that the new hybrids are suitable substrates for the NQO1 protein. It was found that the enzymatic conversion rate depends on the type of 1,4-quinone moiety. Most of the hybrids 11–14 exhibited lower cytotoxicity in vitro than doxorubicin against normal cell lines (HFF-1). The structure-activity relationship showed that the nitrogen atom is necessary to preserve the antiproliferative effect. It should be noted that hybrids showing the highest activity against the lung cancer cell line (A549) also have an overexpression of the gene encoding the NQO1 protein. The selected derivatives were tested for their influence on the expression of H3, TP53, CDKN1A, BAX, and BCL-2 genes. It was shown that the tested compounds are able to activate the mitochondrial apoptosis pathway in A549 cells. A molecular docking study was used to examine the interaction between NQO1 protein and selected hybrids. The results showed that the 1,4-quinone moiety interacts with the enzyme active site through hydrogen bonding and hydrophobic interactions.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27196206/s1, Table S1: The NQO1 activity of hybrids 11–14 and ST monitored at the absorbance of A340 nm.; Table S2: The selectivity index (SI) value for compounds 11–14 and cisplatin.; Table S3: Interaction of selected hybrids with the active site of NQO1 protein.; Figure S1. Visualization of hydrogen bond (green) and hydrophobic interactions (violet) between NQO1 enzyme and hybrid: (a) 11b; (b) 12b; (c) 13b; (d) 14b; Figure S12: Spectra of 6-chloro-7-(quinoline-8-yloxy)quinoline-5,8-dione (11a).; Figure S3: Spectra of 6-chloro-7-[(2-methylquinolin-8-yl)oxy]quinoline-5,8-dione (11b).; Figure S4: Spectra of 8-[(6-chloro-5,8-dioxo-5,8-dihydroquinolin-7-yl)oxy]quinoline-2-carbaldehyde (11c).; Figure S5: Spectra of 6-chloro-7-[(2-chloroquinolin-8-yl)oxy]quinoline-5,8-dione (11d).; Figure S6: Spectrum of 6-chloro-7-{[2-(pyrrolidin-1-yl)quinolin-8-yl]oxy}quinoline-5,8-dione (11e).; Figure S7: Spectra of 6-chloro-7-{[2-(morpholin-4-yl)quinolin-8-yl]oxy}quinoline-5,8-dione (11f).; Figure S8: Spectra of 6-chloro-2-methyl-7-(quinoline-8-yloxy)quinoline-5,8-dione (12a).; Figure S9: Spectra of 6-chloro-2-methyl-7-[(2-methylquinolin-8-yl)oxy]quinoline-5,8-dione (12b).; Figure S10: Spectra of 8-[(6-chloro-2-methyl-5,8-dioxo-5,8-dihydroquinolin-7-yl)oxy]quinoline-2-carbaldehyde (12c).; Figure S11: Spectra of 6-chloro-2-methyl-7-[(2-chloroquinolin-8-yl)oxy]quinoline-5,8-dione (12d).; Figure S12: Spectra of 6-chloro-2-methyl-7-{[2-(pyrrolidin-1-yl)quinolin-8-yl]oxy}quinoline-5,8-dione (12e).; Figure S13: Spectra of 6-chloro-2-methyl-7-{[2-(morpholin-4-yl)quinolin-8-yl]oxy}quinoline-5,8-dione (12f).; Figure S14: Spectra of 6-chloro-7-(quinoline-8-yloxy)isoquinoline-5,8-dione (13a).; Figure S15: Spectra of 6-chloro-7-[(2-methylquinolin-8-yl)oxy]isoquinoline-5,8-dione (13b).; Figure S16: Spectra of 8-[(6-chloro-5,8-dioxo-5,8-dihydroquinolin-7-yl)oxy]isoquinoline-2-carbaldehyde (13c).; Figure S17: Spectra of 6-chloro-7-[(2-chloroquinolin-8-yl)oxy]isoquinoline-5,8-dione (13d).; Figure S18: Spectra of 6-chloro-7-{[2-(pyrrolidin-1-yl)quinolin-8-yl]oxy}isoquinoline-5,8-dione (13e).; Figure S19: Spectra of 6-chloro-7-{[2-(morpholin-4-yl)quinolin-8-yl]oxy}isoquinoline-5,8-dione (13f).; Figure S20: Spectra of 2-chloro-3-[(quinolin-8-yl)oxy]naphthalene-1,4-dione (14a).; Figure S21: Spectra of 2-chloro-3-[(2-methylquinolin-8-yl)oxy]naphthalene-1,4-dione (14b).; Figure S22: Spectra of 8-[(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)oxy]quinoline-2-carbaldehyde (14c).; Figure S23: Spectra of 2-chloro-3-[(2-chloroquinolin-8-yl)oxy]naphthalene-1,4-dione (14d).; Figure S24: Spectra of 2-chloro-3-{[2-(pyrrolidin-1-yl)quinolin-8-yl]oxy}naphthalene-1,4-dione (14e).; Figure S25: Spectra of 2-chloro-3-{[2-(morpholin-4-yl)quinolin-8-yl]oxy}naphthalene-1,4-dione (14f).

Author Contributions

M.K.-T. developed the concept of the work, performed experiments, and wrote the paper. M.J. analyzed spectra. M.L. conducted a study of biological activity. E.B. and E.C. contributed to the purification of all compounds. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by National Science Centre (Poland) grant number 2021/05/X/NZ7/00187.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of compounds 1–14 are available from the authors.

References

  1. Van de Walle, T.; Cools, L.; Mangelinckx, S.; D’hooghe, M. Recent contributions of quinolines to antimalarial and anticancer drug discovery research. Eur. J. Med. Chem. 2021, 226, 113865. [Google Scholar] [CrossRef] [PubMed]
  2. Akkachairin, B.; Rodphon, W.; Reamtong, O.; Mungthin, M.; Tummatorn, J.; Thongsornkleeb, C.; Ruchirawat, S. Synthesis of neocryptolepines and carbocycle-fused quinolines and evaluation of their anticancer and antiplasmodial activities. Bioorg. Chem. 2020, 98, 103732. [Google Scholar] [CrossRef] [PubMed]
  3. Matada, B.S.; Pattanashettar, R.; Yernale, N.G. A comprehensive review on the biological interest of quinoline and its derivatives. Bioorg. Med. Chem. 2021, 32, 115973. [Google Scholar] [CrossRef]
  4. Hu, Y.Q.; Gao, C.; Zhang, S.; Xu, L.; Xu, Z.; Feng, L.S.; Wu, X.; Zhao, F. Quinoline hybrids and their antiplasmodial and antimalarial activities. Eur. J. Med. Chem. 2017, 139, 22–47. [Google Scholar] [CrossRef]
  5. Yadav, P.; Shah, K. Quinolines, a perpetual, multipurpose scaffold in medicinal chemistry. Bioorg. Chem. 2021, 109, 104639. [Google Scholar] [CrossRef] [PubMed]
  6. Afzal, O.; Kumar, S.; Haider, M.R.; Ali, M.D.; Kumar, R.; Jaggi, M.; Bawa, S. A review on anticancer potential of bioactive heterocycle quinoline. Eur. J. Med. Chem. 2015, 5, 871–910. [Google Scholar] [CrossRef] [PubMed]
  7. Lauria, A.; La Monica, G.; Bono, A.; Martorana, A. Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets. Eur. J. Med. Chem. 2021, 220, 113555. [Google Scholar] [CrossRef]
  8. Ahmad, S.S.; Rahi, M.; Ranjan, V.; Sharma, A. Mefloquine as a prophylaxis for malaria needs to be revisited. Int. J. Parasitol. Drugs Drug Resist. 2021, 17, 23–26. [Google Scholar] [CrossRef]
  9. Zhang, G.F.; Liu, X.; Zhang, S.; Pan, B.; Liu, M.L. Ciprofloxacin derivatives and their antibacterial activities. Eur. J. Med. Chem. 2018, 146, 99–612. [Google Scholar] [CrossRef]
  10. Zhou, W.; Wang, H.; Yang, Y.; Chen, Z.S.; Zou, C.; Zhang, J. Chloroquine against malaria, cancers and viral diseases. Drug Discov. Today 2020, 25, 2012–2022. [Google Scholar] [CrossRef]
  11. Lorusso, D.; Pietragalla, A.; Mainenti, S.; Masciullo, V.; Di Vagno, G.; Scambia, G. Review role of topotecan in gynaecological cancers: Current indications and perspectives. Crit. Rev. Oncol. Hematol. 2010, 74, 163–174. [Google Scholar] [CrossRef] [PubMed]
  12. Mulchin, B.J.; Newton, C.G.; Baty, J.W.; Grasso, C.H.; Martin, W.J.; Walton, M.C.; Dangerfield, E.M.; Plunkett, C.H.; Berridge, M.V.; Harper, J.L.; et al. The anti-cancer, anti-inflammatory and tuberculostatic activities of a series of 6,7-substituted-5,8-quinolinequinones. Bioorg. Med. Chem. 2010, 18, 3238–3251. [Google Scholar] [CrossRef] [PubMed]
  13. Kadela-Tomanek, M.; Bębenek, E.; Chrobak, E.; Boryczka, S. 5,8-Quinolinedione scaffold as a promising moiety of bioactive agents. Molecules 2019, 24, 4115. [Google Scholar] [CrossRef]
  14. Kadela, M.; Jastrzębska, M.; Bębenek, E.; Chrobak, E.; Latocha, M.; Kusz, J.; Książek, M.; Boryczka, S. Synthesis, structure and cytotoxic activity of mono- and dialkoxy derivatives of 5,8-quinolinedione. Molecules 2016, 21, 156. [Google Scholar] [CrossRef] [PubMed]
  15. Kadela-Tomanek, M.; Bębenek, E.; Chrobak, E.; Latocha, M.; Boryczka, S. Alkoxy and enediyne derivatives containing 1,4-benzoquinone subuni–s—Synthesis and antitumor activity. Molecules 2017, 22, 447. [Google Scholar] [CrossRef] [PubMed]
  16. Li, G.; Li, Q.; Sun, H.; Li, W. Novel diosgenin-1,4-quinone hybrids: Synthesis, antitumor evaluation, and mechanism studies. J. Steroid Biochem. Mol. Biol. 2021, 214, 105993. [Google Scholar] [CrossRef]
  17. Winski, S.; Hargreaves, R.; Butler, J.; Ross, D. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: Identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin. Cancer Res. 1998, 4, 3083–3088. [Google Scholar]
  18. Siegel, D.; McGuinness, S.; Winski, S.; Ross, D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenet 1999, 9, 113–121. [Google Scholar] [CrossRef]
  19. Siegel, D.; Ross, D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radical. Biol. Med. 2000, 29, 246–253. [Google Scholar] [CrossRef]
  20. Ross, D.; Siegel, D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol. 2004, 382, 115–144. [Google Scholar]
  21. Fryatt, T.; Goroski, D.; Nilson, Z.; Moody, C.; Beall, H. Novel quinolinequinone antitumor agents: Structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1). Bioorg. Med. Chem. Lett. 1999, 9, 2195–2198. [Google Scholar] [CrossRef]
  22. Ryu, C.K.; Jeong, H.J.; Lee, S.; You, H.J.; Chio, K.; Shim, J.Y.; Heo, Y.; Lee, C.O. Effects of 6-arylamine-5,8-quinolinediones and 6-chloro 7-arylo-5,8-isoquinolinediones on NAD(P)H:Quinone Oxidoreductase (NQO1) activity and their cytotoxic potential. Arch. Pharm. Res. 2001, 24, 390–396. [Google Scholar] [CrossRef] [PubMed]
  23. Bian, J.; Deng, B.; Xu, L.; Xu, X.; Wang, N.; Hu, T.; Yao, Z.; Du, J.; Yang, L.; Lei, Y.; et al. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1). Eur. J. Med. Chem. 2014, 82, 56–67. [Google Scholar] [CrossRef] [PubMed]
  24. Boger, D.L.; Yasuda, M.; Mitscher, L.A.; Drake, S.D.; Kitos, P.A.; Thompson, S.C. Streptonigrin and lavendamycin partial structures. Probes for the minimum, potent pharmacophore of streptonigrin, lavendamycin, and synthetic quinoline-5,8-diones. J. Med. Chem. 1987, 30, 1918–1928. [Google Scholar] [CrossRef]
  25. Bolzán, A.D.; Bianchi, M.S. Genotoxicity of streptonigrin: A review. Mutat. Res. 2001, 488, 25–37. [Google Scholar] [CrossRef]
  26. Qiao, K.; Wan, L.; Sun, X.; Zhang, K.; Zhu, N.; Li, X.; Guo, K. Regioselective chlorination of quinoline N-oxides and isoquinoline N-oxides using PPh3/Cl3CCN. Eur. J. Org. Chem. 2016, 2016, 1606–1611. [Google Scholar] [CrossRef]
  27. Wu, M.Y.; Esteban, G.; Brogi, S.; Shionoya, M.; Wang, L.; Campiani, G.; Unzeta, U.; Inokuchi, T.; Butini, S.; Marco-Contelles, J. Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation. Eur. J. Med. Chem. 2016, 121, 864–879. [Google Scholar] [CrossRef]
  28. Kadela-Tomanek, M.; Bębenek, E.; Chrobak, E.; Marciniec, K.; Latocha, M.; Kuśmierz, D.; Jastrzębska, M.; Boryczka, S. Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme. Eur. J. Med. Chem. 2019, 177, 302–315. [Google Scholar] [CrossRef]
  29. Kadela-Tomanek, M.; Jastrzębska, M.; Marciniec, K.; Chrobak, E.; Bębenek, E.; Latocha, M.; Kuśmierz, D.; Boryczka, S. Design, synthesis and biological activity of 1,4-quinone moiety attached to betulin derivatives as potent DT-diaphorase substrate. Bioorg. Chem. 2021, 106, 104478. [Google Scholar] [CrossRef]
  30. Ling, Y.; Yang, Q.X.; Teng, Y.N.; Chen, S.; Gao, W.J.; Guo, J.; Hsu, P.L.; Liu, Y.; Morris-Natschke, S.L.; Hung, C.C.; et al. Development of novel amino-quinoline-5,8-dione derivatives as NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with potent antiproliferative activities. Eur. J. Med. Chem. 2018, 154, 199–209. [Google Scholar] [CrossRef]
  31. Modranka, J.; Drogosz-Stachowicz, J.; Pietrzak, A.; Janecka, A.; Janecki, T. Synthesis and structure-activity relationship study of novel 3-diethoxyphosphorylfuroquinoline-4,9-diones with potent antitumor efficacy. Eur. J. Med. Chem. 2021, 219, 113429. [Google Scholar] [CrossRef] [PubMed]
  32. Wu, L.Q.; Ma, X.; Zhang, C.; Liu, Z.P. Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents. Eur. J. Med. Chem. 2020, 198, 112396. [Google Scholar] [CrossRef] [PubMed]
  33. Dai, X.; Cheng, H.; Bai, Z.; Li, J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J. Cancer 2017, 8, 3131–3141. [Google Scholar] [CrossRef] [PubMed]
  34. Uhlén, M. Tissue-based map of the human proteome. Science 2015, 347, 1260419. [Google Scholar] [CrossRef]
  35. Uhlen, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, K.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S.; et al. Towards a knowledge-based human protein atlas. Nat. Biotechnol. 2010, 28, 1248–1250. [Google Scholar] [CrossRef]
  36. Beyfuss, K.; Hood, D.A. A systematic review of p53 regulation of oxidative stress in skeletal muscle. Redox Rep. 2018, 23, 100–117. [Google Scholar] [CrossRef]
  37. Pizzino, G.; Irrera, N.; Cucinotta, M.; Pallio, G.; Mannino, F.; Arcoraci, V.; Squadrito, F.; Altavilla, D.; Bitto, A. Oxidative stress: Harms and benefits for human health. Oxid. Med. Cell. Longev. 2017, 2017, 8416763. [Google Scholar] [CrossRef]
  38. Dlamini, Z.; Mbita, Z.; Zungu, M. Genealogy, expression, and molecular mechanisms in apoptosis. Pharmacol. Ther. 2004, 101, 1–15. [Google Scholar] [CrossRef]
  39. Yu, J.; Zhang, L. The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. 2005, 331, 851–858. [Google Scholar] [CrossRef]
  40. Barr, A.R.; Cooper, S.; Heldt, F.S.; Butera, F.; Stoy, H.; Mansfeld, J.; Novak, B.; Bakal, C. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nat. Commun. 2017, 8, 14728–14745. [Google Scholar] [CrossRef]
  41. Yip, K.W.; Reed, J.C. Bcl-2 family proteins and cancer. Oncogene 2008, 27, 6398–6406. [Google Scholar] [CrossRef] [PubMed]
  42. Woods, J.J.; Unnerstall, R.; Hasson, A.; Abou, D.S.; Radchenko, V.; Thorek, D.L.J.; WIlson, J.J. Stable chelation of the uranyl ion by acyclic hexadentate ligands: Potential applications for 230U targeted α-therapy. Inorg. Chem. 2022, 61, 3337–3350. [Google Scholar] [CrossRef]
  43. Batenko, N.; Popova, O.; Belyakov, S.; Valters, R. Synthesis of aminovinyl derivatives of quinoline- and isoquinoline-5,8-diones. Chem. Heterocycl. Compounds 2012, 48, 888–891. [Google Scholar] [CrossRef]
  44. Gupta, A.; Kumar, J.; Bhadra, S. Chelation-assisted de-aryloxylative amination of 2-aryloxy quinolines: A new synthetic route to a key fragment of a bioactive PRMT5 inhibitor. Org. Biomol. Chem. 2018, 16, 3716–3720. [Google Scholar] [CrossRef] [PubMed]
  45. Li, X.; Bian, J.; Wang, N.; Qian, X.; Gu, J.; Mu, T.; Fan, J.; Yang, X.; Li, S.; Yang, T.; et al. Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation. Bioorg. Med. Chem. 2016, 24, 1006–1013. [Google Scholar] [CrossRef] [PubMed]
  46. Asher, G.; Dym, O.; Tsvetkov, P.; Adler, J.; Shaul, Y. The crystal structure of NAD(P)H Quinone Oxidoreductase 1 in complex with its potent inhibitor dicoumarol. Biochemistry 2006, 45, 6372–6378. [Google Scholar] [CrossRef]
  47. Trott, O.; Olson, A. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [Google Scholar] [CrossRef] [Green Version]
  48. BIOVIA. Discovery Studio Modeling Environment; Release 2017; Dessault Systemes: San Diego, CA, USA, 2016. [Google Scholar]
Molecules 27 06206 g001 550
Figure 1. The design of title hybrids 5,8-quinolinedione (blue) connected by an oxygen atom with a quinoline (pink) moiety.
Figure 1. The design of title hybrids 5,8-quinolinedione (blue) connected by an oxygen atom with a quinoline (pink) moiety.
Molecules 27 06206 g001
Molecules 27 06206 sch001 550
Scheme 1. Synthesis route of compounds 3–6. Reagents: (a) mCBPA, CH2Cl2, rt, 12 h; (b) PPh3, Cl3CCN, toluene, reflux, 4 h; (c); amine, MW, 110 °C, 10 min; (d) SeO2, dioxane, reflux, 24 h.
Scheme 1. Synthesis route of compounds 3–6. Reagents: (a) mCBPA, CH2Cl2, rt, 12 h; (b) PPh3, Cl3CCN, toluene, reflux, 4 h; (c); amine, MW, 110 °C, 10 min; (d) SeO2, dioxane, reflux, 24 h.
Molecules 27 06206 sch001
Molecules 27 06206 sch002 550
Scheme 2. Synthesis route of hybrids 11–14. Reagents: (a) K2CO3, THF, rt, 24 h.
Scheme 2. Synthesis route of hybrids 11–14. Reagents: (a) K2CO3, THF, rt, 24 h.
Molecules 27 06206 sch002
Molecules 27 06206 g002 550
Figure 2. Enzymatic conversion rate of NQO1 of hybrids 11–14 and streptonigrin (ST) monitored at the absorbance of A340 nm.
Figure 2. Enzymatic conversion rate of NQO1 of hybrids 11–14 and streptonigrin (ST) monitored at the absorbance of A340 nm.
Molecules 27 06206 g002
Molecules 27 06206 g003 550
Figure 3. Effect of hybrids 11b, 12b, 13b and 14b on transcriptional activity of: (a) H3; (b) TP53; (c) CDKN1A; (d) BAX/BCL-2 for A549 cells. * p < 0.05 compared with the untreated control.
Figure 3. Effect of hybrids 11b, 12b, 13b and 14b on transcriptional activity of: (a) H3; (b) TP53; (c) CDKN1A; (d) BAX/BCL-2 for A549 cells. * p < 0.05 compared with the untreated control.
Molecules 27 06206 g003
Molecules 27 06206 g004 550
Figure 4. Superposition of docked ligands: 11b (green), 12b (yellow), 13b (violet), 14b (blue), and FAD cofactor (black) in the binding site of the NQO1 enzyme. Protein is colored according to its hydrophobicity scale.
Figure 4. Superposition of docked ligands: 11b (green), 12b (yellow), 13b (violet), 14b (blue), and FAD cofactor (black) in the binding site of the NQO1 enzyme. Protein is colored according to its hydrophobicity scale.
Molecules 27 06206 g004
Molecules 27 06206 g005a 550Molecules 27 06206 g005b 550
Figure 5. Visualization of interactions between NQO1 enzyme and hybrid: (a) 11b; (b) 12b; (c) 13b; (d) 14b.
Figure 5. Visualization of interactions between NQO1 enzyme and hybrid: (a) 11b; (b) 12b; (c) 13b; (d) 14b.
Molecules 27 06206 g005aMolecules 27 06206 g005b
Table
Table 1. The biological activity of compounds 11–14 and doxorubicin.
Table 1. The biological activity of compounds 11–14 and doxorubicin.
CompoundCell Line/IC50 (µM)
Colo-829SK-OV-3MDA-MB-231T47DMCF-7A549HFF-1
11a18.51 ± 1.311.55 ± 0.2011.49 ± 0.1918.68 ± 0.7119.35 ± 0.371.68 ± 0.0510.21 ± 0.16
11b1.92 ± 0.111.69 ± 0.031.64 ± 0.152.42 ± 0.132.11 ± 0.081.78 ± 0.2126.06 ± 1.02
11c11.65 ± 1.361.78 ± 0.3114.35 ± 2.0122.19 ± 0.6618.33 ± 1.231.45 ± 0.1310.52 ± 0.87
11d1.45 ± 0.241.56 ± 0.112.03 ± 0.052.10 ± 0.112.11 ± 0.091.71 ± 0.0313.74 ± 1.27
11e15.01 ± 0.321.72 ± 0.091.97 ± 0.1320.79 ± 1.032.03 ± 0.0312.12 ± 1.0611.45 ± 0.69
11f14.04 ± 1.1610.89 ± 0.4813.75 ± 1.0918.62 ± 0.6216.21 ± 0.1212.63 ± 0.8225.64 ± 0.19
12a1.52 ± 0.350.05 ± 0.021.97 ± 0.151.59 ± 0.152.09 ± 0.020.85 ± 0.0417.34 ± 0.89
12b1.69 ± 0.081.49 ± 0.211.57 ± 0.191.90 ± 0.231.78 ± 0.031.43 ± 0.0610.15 ± 1.33
12c14.55 ± 0.512.16 ± 0.1921.12 ± 0.1123.26 ± 1.1219.11 ± 0.953.14 ± 0.4317.89 ± 1.37
12d13.12 ± 0.4915.38 ± 0.4815.55 ± 0.7916.17 ± 0.9817.41 ± 0.821.46 ± 0.0610.28 ± 1.65
12e1.53 ± 0.081.05 ± 0.061.50 ± 0.1517.35 ± 1.301.89 ± 0.2315.12 ± 0.3917.56 ± 1.05
12f13.35 ± 0.2113.49 ± 0.2110.22 ± 0.2817.34 ± 0.2614.11 ± 0.6711.56 ± 0.7219.93 ± 0.93
13a0.17 ± 0.020.46 ± 0.021.02 ± 0.150.09 ± 0.041.16 ± 0.150.03 ± 0.0127.69 ± 0.70
13b0.39 ± 0.110.49 ± 0.050.11 ± 0.011.29 ± 0.030.61 ± 0.090.57 ± 0.0226.04 ± 1.60
13c0.34 ± 0.280.32 ± 0.010.75 ± 0.090.52 ± 0.080.89 ± 0.031.32 ± 0.3213.25 ± 0.85
13d1.96 ± 0.0817.08 ± 1.761.67 ± 0.11Neg.1.75 ± 0.190.06 ± 0.0111.09 ± 1.07
13e19.57 ± 1.3215.85 ± 0.2616.61 ± 0.38Neg.16.85 ± 0.5014.04 ± 0.2615.52 ± 0.72
13f2.10 ± 0.061.23 ± 0.080.13 ± 0.052.15 ± 0.061.03 ± 0.191.22 ± 0.0818.39 ± 0.35
14a15.30 ± 2.561.70 ± 0.2915.22 ± 0.85Neg.14.07 ± 0.980.65 ± 0.0712.81 ± 0.85
14b15.04 ± 1.0316.78 ± 0.5919.15 ± 0.6222.16 ± 1.0316.31 ± 1.082.10 ± 0.2911.14 ± 1.62
14cNeg.0.25 ± 0.0625.14 ± 0.971.62 ± 0.21Neg.0.41 ± 0.0617.96 ± 1.75
14d17.98 ± 2.0114.12 ± 0.522.05 ± 0.35Neg.11.66 ± 1.348.13 ± 1.0214.32 ± 1.23
14e22.00 ± 0.6015.92 ± 0.227.66 ± 1.12Neg.24.05 ± 0.2122.14 ± 0.8918.65 ± 1.36
14f11.35 ± 1.9714.16 ± 0.762.35 ± 0.09Neg.17.45 ± 1.0214.02 ± 0.8620.30 ± 0.87
Doxorubicin0.05 ± 0.010.15 ± 0.030.64 ± 0.060.04 ± 0.010.12 ± 0.050.02 ± 0.010.12 ± 0.03
Neg. means that IC50 > 30 µM.
Table
Table 2. Scoring values (ΔG) of hybrids 1–24 and streptonigrin (ST).
Table 2. Scoring values (ΔG) of hybrids 1–24 and streptonigrin (ST).
LigandΔG (kcal/mol)LigandΔG (kcal/mol)
11a−10.113a−10.4
11b−10.413b−10.7
11c−10.313c−9.9
11d−10.013d−10.9
11e−10.913e−10.6
11f−10.113f−10.8
12a−10.314a−10.3
12b−10.614b−10.1
12c−10.514c−9.7
12d−10.614d−9.5
12e−10.214e−9.4
12f−10.314f−9.6
ST−7.1
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kadela-Tomanek, M.; Jastrzębska, M.; Chrobak, E.; Bębenek, E.; Latocha, M. Hybrids of 1,4-Quinone with Quinoline Derivatives: Synthesis, Biological Activity, and Molecular Docking with DT-Diaphorase (NQO1). Molecules 2022, 27, 6206. https://doi.org/10.3390/molecules27196206

AMA Style

Kadela-Tomanek M, Jastrzębska M, Chrobak E, Bębenek E, Latocha M. Hybrids of 1,4-Quinone with Quinoline Derivatives: Synthesis, Biological Activity, and Molecular Docking with DT-Diaphorase (NQO1). Molecules. 2022; 27(19):6206. https://doi.org/10.3390/molecules27196206

Chicago/Turabian Style

Kadela-Tomanek, Monika, Maria Jastrzębska, Elwira Chrobak, Ewa Bębenek, and Małgorzata Latocha. 2022. "Hybrids of 1,4-Quinone with Quinoline Derivatives: Synthesis, Biological Activity, and Molecular Docking with DT-Diaphorase (NQO1)" Molecules 27, no. 19: 6206. https://doi.org/10.3390/molecules27196206

Article Metrics

Back to TopTop